1. Cell Cycle/DNA Damage
    Epigenetics
  2. Aurora Kinase

SCH-1473759 

Cat. No.: HY-10482 Purity: 98.20%
Data Sheet SDS Handling Instructions

SCH-1473759 is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively.

For research use only. We do not sell to patients.
SCH-1473759 Chemical Structure

SCH-1473759 Chemical Structure

CAS No. : 1094069-99-4

Size Price Stock Quantity
10 mM * 1 mL in DMSO $206 In-stock
2 mg $120 In-stock
5 mg $220 In-stock
10 mg $320 In-stock
50 mg $750 Get quote
100 mg $1150 Get quote
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of SCH-1473759:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

SCH-1473759 is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively.

IC50 & Target

IC50: 4 nM (Aurora A), 13 nM (Aurora B)[1]

In Vitro

SCH-1473759 directly binds to aurora A and B with Kds of 20 and 30 nM, respectively. SCH-1473759 also inhibits the Src family of kinases (IC50<10 nM), Chk1 (IC50=13 nM), VEGFR2 (IC50=1 nM), and IRAK4 (IC50=37 nM). It does not have significant activity (IC50>1000 nM) against 34 other kinases representing different families of the kinome. SCH-1473759 inhibits HCT116 cells proliferation with an IC50 of 6 nM[1]. SCH 1473759 inhibits tumor cell lines from different tissues (breast, ovarian, prostate, lung, colon, brain, gastric, renal, skin, and leukemia). The most sensitive cell lines includ A2780, LNCap, N87, Molt4, K562, and CCRF-CEM with IC50 values <5 nM[2].

In Vivo

SCH-1473759 at a low dose of 5 mg/kg (ip, bid) is well-tolerated in a continuous dosing schedule and shows 50% tumor growth inhibition(TGI) on day 16. A higher dose of 10mg/kg(ip, bid) is well-tolerated in an intermittent schedule (5 days on, 5 days off) and gave 69% TGI on day 16. SCH-1473759 shows good exposure in all species with the clearance being high in rodents and moderate in dog and monkey. The half-life is also moderate, but the tissue distribution is high[1]. SCH 1473759 dose- and schedule-dependent anti-tumor activity in four human tumor xenograft models. Further, the efficacy is enhanced in combination with taxanes and found to be most efficacious when SCH 1473759 is dosed 12-h post-taxane treatment[2].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.3444 mL 11.7222 mL 23.4445 mL
5 mM 0.4689 mL 2.3444 mL 4.6889 mL
10 mM 0.2344 mL 1.1722 mL 2.3444 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay
[1]

Aurora A and Aurora B kinase assays are performed in low protein binding 384-well plates. SCH-1473759 is diluted in 100% DMSO to the desired concentrations. For the Aurora A assay, each reaction consists of 8 nM enzyme Aurora A, 100 nM Tamra-PKAtide, 25μM ATP, 1 mM DTT, and kinase buffer. For the Aurora B assay, each reaction consisted of 26 nM enzyme Aurora B, 100 nM Tamra-PKAtide, 50 μM ATP, 1 mM DTT, and kinase buffer. Dose-response curves are plotted from inhibition data generated in duplicate, from 8 point serial dilutions of SCH-1473759[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

SCH-1473759 is prepared in 0.1% DMSO[1].

Cells are plated at a cell density ranging from 625 to 3,750 cells per well and treated in triplicate wells with SCH-1473759 (0.1% final DMSO concentration). A plate is stained at the start of the study (zero hour) and a second plate is incubated for 72 hour at 37°C and then stained. Cells are fixed with fixation solution plus 1,000 nM Hoechst 33342 dye and incubated for 30 minutes. The fixation solution is removed and cells are ished twice with PBS. Then 15 immunofluorescence images are captured at 10X using automated fluorescent microscope [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

SCH-1473759 is dissolved in 20% hydroxypropyl B cyclodextrin (HPBCD)[1].

Mouse: Anti-tumor efficacy of SCH 1473759 dosed i.p. is evaluated in mice bearing established A2780 ovarian tumor xenografts. Three schedules are tested at their respective maximum tolerated doses: 10 mg/kg bid (twice daily), 20 mg/kg qd (daily), and 100 mg/kg day 0, 4, 7. Additionally, 60 mg/kg day 0, 4, 7 is tested[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

426.54

Formula

C₂₀H₂₆N₈OS

CAS No.

1094069-99-4

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SCH-1473759
Cat. No.:
HY-10482
Quantity: